share_log

Transcode Therapeutics | 8-K: Current report

SEC announcement ·  Apr 5 16:55
Summary by Moomoo AI
TransCode Therapeutics, Inc., a clinical-stage oncology company, announced its financial results for the fourth quarter and full year ended December 31, 2023, on April 3, 2024. The company, which specializes in RNA therapeutics for cancer treatment, reported progress in its clinical trials and strategic collaborations. TransCode advanced its lead therapeutic candidate, TTX-MC138, into clinical trials as a first-in-class drug candidate targeting metastatic cancer. Despite a challenging financial market, the company raised over $25 million in equity financings. TransCode also signed agreements with Debiopharm and Akribion Genomics to develop cancer treatments and a CRISPR-derived technology platform, respectively. The company appointed Tom Fitzgerald as interim CEO and CFO, and Daniel Vlock, M.D., as Chief Medical Officer. TransCode regained compliance with Nasdaq's...Show More
TransCode Therapeutics, Inc., a clinical-stage oncology company, announced its financial results for the fourth quarter and full year ended December 31, 2023, on April 3, 2024. The company, which specializes in RNA therapeutics for cancer treatment, reported progress in its clinical trials and strategic collaborations. TransCode advanced its lead therapeutic candidate, TTX-MC138, into clinical trials as a first-in-class drug candidate targeting metastatic cancer. Despite a challenging financial market, the company raised over $25 million in equity financings. TransCode also signed agreements with Debiopharm and Akribion Genomics to develop cancer treatments and a CRISPR-derived technology platform, respectively. The company appointed Tom Fitzgerald as interim CEO and CFO, and Daniel Vlock, M.D., as Chief Medical Officer. TransCode regained compliance with Nasdaq's stockholders' equity requirement and presented its technology at several leading cancer conferences. Financially, TransCode ended the year with $2.8 million in cash and expects the funds, along with proceeds from a January 2024 offering, to sustain operations into late Q3 or early Q4 of 2024. The company's R&D objectives for 2024 include initiating a Phase 1 clinical trial for TTX-MC138, reporting preliminary results, publishing preclinical results, and advancing strategic partnerships.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more